Aicher, Thomas D. published the artcileDiscovery of LYC-55716: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor-¦Ã (ROR¦Ã) Agonist for Use in Treating Cancer, Recommanded Product: (S)-3-(6-(3-(Difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)-2,2-dimethylpropanoic acid, the publication is Journal of Medicinal Chemistry (2021), 64(18), 13410-13428, database is CAplus and MEDLINE.
Retinoic acid receptor-related orphan receptor ¦Ã (RORc, ROR¦Ã, or NR1F3) is the nuclear receptor master transcription factor that drives the function and development of IL-17-producing T helper cells (Th17), cytotoxic T cells (Tc17), and subsets of innate lymphoid cells. Activation of ROR¦Ã+ T cells in the tumor microenvironment is hypothesized to render immune infiltrates more effective at countering tumor growth. To test this hypothesis, a family of benzoxazines was optimized to provide LYC-55716 (37c), a potent, selective, and orally bioavailable small-mol. ROR¦Ã agonist. LYC-55716 decreases tumor growth and enhances survival in preclin. tumor models and was nominated as a clin. development candidate for evaluation in patients with solid tumors.
Journal of Medicinal Chemistry published new progress about 2055536-64-4. 2055536-64-4 belongs to catalysis-chemistry, auxiliary class Metabolic Enzyme,ROR, name is (S)-3-(6-(3-(Difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)-2,2-dimethylpropanoic acid, and the molecular formula is C27H23F6NO6S, Recommanded Product: (S)-3-(6-(3-(Difluoromethoxy)-5-fluorophenyl)-4-((3-(trifluoromethyl)phenyl)sulfonyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)-2,2-dimethylpropanoic acid.
Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia